Medacta Group Stock

Medacta Group Quick Ratio

The Quick Ratio (Acid Test) of Medacta Group (MOVE.SW) as of Aug 19, 2026 is 0.47. In the previous year, Quick Ratio (Acid Test) was 0.61 — a change of -23.16% (lower).

Quick Ratio

0.47

YoY

-23.16%

Last updated:

Quick Ratio (Acid Test) of Medacta Group is 2026 0.47 . Quick Ratio (Acid Test) of Medacta Group was 2025 0.61 . It decreases by -23.16% lower compared to the previous year.
Access this data via the Eulerpool API

Medacta Group Stock analysis

What does Medacta Group do? The Medacta Group SA is a leading global company in the development, manufacturing, and marketing of medical devices and implants for the orthopedic industry. The company was founded in 1999 by Swiss entrepreneur Alberto Siccardi and is headquartered in Switzerland. The Medacta Group SA has its origins in one person - Alberto Siccardi. As a former athlete and successful entrepreneur, he had a vision that he put into action. He founded the Medacta Group and began focusing on the development and manufacturing of innovative orthopedic devices and implants. The Medacta Group has an innovative business model because the company is able to handle everything from research and development to marketing and sales of its products. This means that Medacta combines all steps from idea to end product under one roof and has complete control over the entire process. The Medacta Group SA is divided into three business areas: orthopedics, spine, and sports medicine. In the orthopedic field, the company manufactures hip and knee joint implants, as well as shoulder and elbow implants. Medacta also offers technologies that help extend the lifespan of artificial joints. In the spine field, the company provides instruments and implants for spine surgery. Medacta has a high level of expertise in this field and is known for innovative products that contribute to improving patient treatment. In the sports medicine field, the Medacta Group offers solutions for sports injuries. The company has developed a wide range of technologies and products that accelerate the healing process and support rehabilitation. Some of Medacta's most well-known products are the AMIS (Anterior Minimally Invasive Surgery) hip joint system and the GMK (General Medacta Knee) knee joint system. The AMIS system is a minimally invasive procedure for hip joint surgery that aims to shorten rehabilitation time and reduce the risk of complications. The GMK system is an innovative knee joint system that allows natural joint mechanics and approximates the natural knee pivot point. Medacta has also developed a range of software solutions that support surgeons in the planning and execution of operations. These solutions provide detailed visualizations and allow for precise planning of procedures. In conclusion, the Medacta Group SA is a global leader in the development and manufacturing of medical devices and implants for orthopedics, spine, and sports medicine. The company has an innovative business model that allows for complete control of the entire manufacturing process. Through the development of innovative products and technologies, the Medacta Group supports the treatment and rehabilitation of patients worldwide. Medacta Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medacta Group stock

Quick Ratio (Acid Test) of Medacta Group is 0.47 in 2026.

Quick Ratio (Acid Test) of Medacta Group changed from 0.61 to 0.47, representing a -23.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Quick Ratio (Acid Test) Medacta Group since 2006 – with annual values, charts, and detailed analysis.

The Quick Ratio measures liquidity by comparing liquid assets to current liabilities, excluding inventory. It is a more conservative measure than the current ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Quick Ratio (Acid Test)'s Medacta Group with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Medacta Group

All Key Metrics — Medacta Group